EXOMIND can be profitable in the right practice, but the financial case depends on three variables: capital cost, treatment volume, and per-session pricing in your local market. Patients pay $400-$600 per session, and because there are no per-treatment consumables, gross margin per session is high once fixed costs are covered.
The challenge is fixed costs. Monthly financing payments on a new unit run roughly 2-2.5% of purchase price (5-year amortization at typical equipment rates). Add the service contract (roughly $3,000-$6,000/year after warranty) and operator labor, and the device needs to fill enough session slots monthly to cover the fixed-cost base before generating profit.
For practices that fill the schedule, EXOMIND delivers strong financial returns. For practices that struggle with patient flow, the same device can become a cash drain within 12-18 months. The decision is more about whether your patient pipeline can support the device than whether the device itself is profitable in theory.
EXOMIND break-even analysis
Break-even is the point where treatment revenue covers all fixed and variable costs of owning the device. For EXOMIND, the calculation depends on how you finance the purchase, your per-session pricing, and your treatment volume.
New unit, financed. A practice buying new EXOMIND at the midpoint of $100,000-$200,000 and financing over 60 months at 8% APR has monthly fixed costs of approximately 2-2.5% of purchase price for the loan, plus the service contract (there are no per-treatment consumables). Break-even at $400-$600 per session typically requires 1.5-2.5 sessions per day.
Used unit, financed. A used EXOMIND would cut monthly fixed costs and lower break-even, but the secondary market is essentially nonexistent because the device was only cleared in 2024. In practice, you are modeling break-even on a new unit, not a discounted used one.
Cash purchase. Without monthly financing payments, the practice only needs to cover consumables, maintenance, and labor. Break-even is even lower, but the opportunity cost of tying up cash for 5+ years should be factored into the decision.
Treatment volume sensitivity
The most important variable in EXOMIND ROI is treatment volume. Small changes in daily treatments produce large changes in annual profit because the fixed-cost base is high.
At 1 session per day (about 260/year at $400-$600), EXOMIND generates roughly $104,000-$156,000 in annual revenue. After financing and fixed costs, this typically lands at marginal profitability or small losses for a new unit during ramp-up.
At 2 sessions per day (about 520/year), revenue roughly doubles to $208,000-$312,000. Fixed costs barely change, so net profit margins jump 15 to 25 points. This is the volume target most EXOMIND buyers should plan for.
At 3+ sessions per day (780+/year), revenue reaches $312,000-$468,000 and EXOMIND becomes solidly profitable, with net margins of 50-70% achievable. This is the upside scenario for established practices with consistent patient flow.
The most common ROI mistake is projecting 4-6 daily treatments before patient demand is validated. Year-one volume rarely matches optimistic projections. Plan for ramp-up and confirm the device is profitable at conservative volume assumptions before signing the purchase contract.
EXOMIND pricing strategy
Per-session pricing is the second-most important variable in EXOMIND ROI. Standard pricing runs $400-$600 per session, or roughly $3,000-$4,800 for the six-session depression course, with urban cash-pay practices commanding the top of the range and lower-volume practices discounting. Most clinics package the full course rather than billing session by session, which improves completion and protects revenue.
Pricing strategy depends on your patient mix and competitive positioning. Concierge and urban psychiatry practices can hold the top of the range; suburban practices typically charge mid-range; and price-sensitive markets discount toward the floor. Because EXOMIND is cash-pay with no insurance reimbursement, your local out-of-pocket demand sets the ceiling.
Discounting can improve volume but quickly erodes ROI. A 20% price cut requires 25% more volume just to hold the same gross profit. Most practices benefit more from holding pricing and investing in patient acquisition than from cutting prices to fill the schedule.
Five-year financial model
For a practice buying new EXOMIND at midpoint pricing, financing over 60 months at 8% APR, doing 2 treatments per day at midpoint per-session pricing, the rough five-year financial profile looks like:
Year 1: Marginal profit or break-even. Patient acquisition costs and ramp dilute returns. Section 179 tax deduction provides significant first-year tax savings that improve cash flow.
Year 2: Positive net profit. Patient base is built. Margin improves as fixed costs amortize over higher revenue.
Year 3: Strong net profit. Equipment is generating consistent returns. Maintenance contract decisions and consumable costs become the main margin variables.
Year 4: Peak profitability. Loan is partially paid down. Treatment volume is at steady state.
Year 5: Loan paid off (if financed over 60 months). Net profit margin jumps 10 to 15 points as the financing line disappears. Decision point: keep operating, upgrade to newer platform, or sell on secondary market.
This is a typical pattern for successful device investments. Practices that fail to make this curve usually have one of two problems: insufficient patient flow to drive volume, or per-session pricing too low to cover fixed costs. Identify which problem you have early and address it before committing more capital.
How to model EXOMIND ROI for your practice
Before signing a purchase contract, build a simple ROI model with these inputs:
Section 179 tax savings (typically 35% of purchase price in year one)
Per-session pricing (use realistic local-market numbers, not aspirational)
Treatments per day (be conservative; use 60-70% of your aspirational number)
Consumable cost per treatment
Annual maintenance contract cost
Operator labor cost per treatment
Allocated overhead (rent, utilities, marketing)
Run the model at three volume scenarios: conservative (50% of aspirational), realistic (70% of aspirational), and aspirational (100%). If the device fails ROI at the conservative scenario, do not buy it. The most common cause of buyer's remorse is overestimating sustainable treatment volume in year one.
Frequently Asked Questions
How profitable is EXOMIND?
EXOMIND patient pricing runs $400-$600 per session. Because there are no per-treatment consumables, gross margin per session is high. Net profit margin (after capital recovery, the service contract, staffing, and overhead) typically settles at 40-60% in established practices. Actual profitability depends heavily on session volume and local cash-pay demand, since EXOMIND has no established insurance reimbursement.
How long is the EXOMIND payback period?
For a practice running 2-3 sessions per day at $400-$600, a new EXOMIND typically reaches break-even around 12-18 months at the lower end of the $100,000-$200,000 price range and 18-30 months at the high end. There is no real used market yet (cleared 2024) to shortcut payback, so model break-even on a new unit with conservative volume assumptions.
How much revenue can EXOMIND generate per month?
At $400-$600 per session, monthly revenue depends on volume. A practice running 2 sessions per day (about 44 working days a month) generates roughly $17,600-$26,400/month. At 4 sessions per day, that rises to about $35,200-$52,800/month. Most physicians overestimate sustainable volume in year one, so plan for 1-3 daily sessions during ramp-up before assuming higher numbers.
What's the realistic profit margin on EXOMIND?
Gross profit margin per treatment runs 70-85%. After capital recovery, fixed costs, marketing, and staffing, net profit margin typically settles at 40-60% in established practices. Year-one margins are often lower because patient acquisition costs and ramp-up dilute returns. Net margin improves sharply in years 2-3 once the patient base is built.
How many patients per day do I need for EXOMIND to break even?
Break-even volume depends on your purchase price, financing structure, and per-session pricing. For a practice that buys EXOMIND new at the midpoint of the price range and finances over 60 months at 8% APR, break-even is typically 1.5-2.5 treatments per day. Practices with used units or strong patient flow break even faster. Practices with thin patient flow may struggle to cover monthly payments.
Can EXOMIND pay for itself in year one?
Year-one payback on EXOMIND is rare. Capital cost of $100,000-$200,000 is too high to recover from a single year of session volume in most settings, and there is no cheap used unit to shortcut it because the device was only cleared in 2024. A practice with strong existing patient flow and aggressive scheduling can approach payback faster, but conservative planning assumes 2-3 years.
What's the worst-case scenario for EXOMIND ROI?
The worst-case scenario is a practice that buys EXOMIND expecting 4-6 treatments per day and reaches only 0.5-1 treatments per day. At low volume, fixed costs (financing, maintenance, staffing) exceed revenue, and the device becomes a cash drain. This is the most common pattern in failed device investments. Always model worst-case volume before purchase and confirm you can survive 12-18 months at low utilization without financial damage.
Should I buy EXOMIND new or used to optimize ROI?
In theory used equipment delivers better ROI, but for EXOMIND it is largely moot: the device was only cleared in 2024, so there is almost no used inventory to buy. For nearly every buyer the realistic option is a new unit, where the lever to improve ROI is negotiating the new deal (quarter-end timing, BTL bundle pricing) rather than hunting for a discounted used console. New units also keep the warranty, current software, and training that protect early-stage ROI.